We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+39.07%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$465M
Cap. Flow
-$336M
Cap. Flow %
-9.38%
Top 10 Hldgs %
52.59%
Holding
77
New
11
Increased
13
Reduced
21
Closed
21

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$61.5M
2
LBRX
LB Pharmaceuticals
LBRX
+$53.2M
3
EXAS
Exact Sciences
EXAS
+$50M
4
AKRO
Akero Therapeutics
AKRO
+$46.4M
5
PCVX icon
Vaxcyte
PCVX
+$28.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$176M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$87M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$52.9M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$49.1M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$41.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORKA
26
Oruka Therapeutics
ORKA
$5.22B
$51.1M 1.42%
2,654,781
+735,983
+38% +$10.9M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.19B
$48.2M 1.34%
1,200,000
-150,000
-11% -$5.28M
CMPS
28
Compass Pathways
CMPS
$1.48B
$45M 1.26%
7,859,648
-971,359
-11% -$4.36M
ANIP icon
29
ANI Pharmaceuticals
ANIP
$1.85B
$41.2M 1.15%
450,000
-250,000
-36% -$20.4M
BCAX
30
Bicara Therapeutics
BCAX
$1.73B
$38.3M 1.07%
2,426,657
– –
OLMA icon
31
Olema Pharmaceuticals
OLMA
$991M
$34M 0.95%
3,470,172
+27,339
+0.8% +$164K
CDTX
32
DELISTED
Cidara Therapeutics
CDTX
$28.7M 0.8%
300,000
+50,000
+20% +$3.19M
QURE icon
33
uniQure
QURE
$2.79B
$28.2M 0.79%
+483,092
New +$8.77M
DYN icon
34
Dyne Therapeutics
DYN
$4.15B
$25.3M 0.71%
+2,000,000
New +$22.8M
JBIO
35
Jade Biosciences
JBIO
$1.18B
$19.7M 0.55%
2,279,892
-229,409
-9% -$1.87M
RAPT
36
DELISTED
RAPT Therapeutics
RAPT
$19.4M 0.54%
751,422
– –
GHRS icon
37
GH Research
GHRS
$1.95B
$17.9M 0.5%
1,250,000
-750,000
-38% -$10.5M
DFTX
38
Definium Therapeutics
DFTX
$5.59B
$17.7M 0.49%
1,500,000
-1,000,000
-40% -$9.33M
ENGN icon
39
enGene Therapeutics
ENGN
$121M
$15.3M 0.43%
2,239,353
-2,318,222
-51% -$10.6M
GMAB icon
40
Genmab
GMAB
$17.6B
$14.8M 0.41%
+481,267
New +$11.7M
TNGX icon
41
Tango Therapeutics
TNGX
$4.21B
$12.2M 0.34%
+1,454,562
New +$9.84M
CNTX icon
42
Context Therapeutics
CNTX
$54.2M
$7.19M 0.2%
7,419,355
– –
IMA
43
ImageneBio Inc
IMA
$64.4M
$7.16M 0.2%
878,516
+668,890
+319% +$8.87M
XNCR icon
44
Xencor
XNCR
$1.47B
$6.44M 0.18%
549,439
– –
HELP
45
Cybin Inc
HELP
$498M
$5.89M 0.16%
1,000,000
-529,987
-35% -$3.76M
CRMD icon
46
CorMedix
CRMD
$566M
$5.82M 0.16%
+500,000
New +$6.05M
PEPG icon
47
PepGen
PEPG
$120M
$5.54M 0.15%
+1,200,000
New +$1.93M
CBIO
48
Crescent Biopharma
CBIO
$568M
$5.39M 0.15%
453,686
– –
ALGS icon
49
Aligos Therapeutics
ALGS
$26.5M
$4.35M 0.12%
444,110
– –
AUTL
50
Autolus Therapeutics
AUTL
$381M
$4.19M 0.12%
2,568,613
-14,283,534
-85% -$27.9M
1
2
3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Deep Track Capital held 77 positions worth $3.58B, up 15% from $3.12B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Deep Track Capital withdrew a net $336M in Q3 2025, closing 21 positions and reducing 21 holdings. Its most notable exit was Insmed, an estimated $176M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in LB Pharmaceuticals worth $52.9M.

  • Deep Track Capital's largest Q3 2025 buy was LB Pharmaceuticals: 3,352,804 shares worth $52.9M.
  • Deep Track Capital added most to Tarsus Pharmaceuticals in Q3 2025, an estimated $61.5M increase.
  • Deep Track Capital's biggest Q3 2025 reduction was Protagonist Therapeutics, cutting an estimated $87M.
  • Deep Track Capital fully exited Insmed in Q3 2025, selling an estimated $176M.
  • Deep Track Capital's ten largest holdings make up 53% of its $3.58B portfolio in Q3 2025.
  • Deep Track Capital opened 11 new positions and closed 21 in Q3 2025.
  • Deep Track Capital's portfolio value rose 15% quarter-over-quarter to $3.58B.

Based on Deep Track Capital's 13F filing for Q3 2025, filed 14 Nov 2025.